Summary by Moomoo AI
Jay S. Duker, President and CEO of EyePoint Pharmaceuticals, executed multiple stock transactions on January 5-6, 2025. Duker acquired a total of 50,794 shares of common stock through the exercise of derivative securities at $0 per share. Simultaneously, he disposed of 16,115 shares at prices ranging from $8.26 to $8.68 per share, generating approximately $135,676 in total market value.The transactions were completed through a combination of exercises and tax-related dispositions. On January 5, Duker acquired 30,000 shares and sold 10,007 shares. The following day, he acquired an additional 20,794 shares and disposed of 6,108 shares. These actions were reported as direct ownership transactions.Following these transactions, Duker's direct ownership in EyePoint Pharmaceuticals stands at 72,706 shares. Additionally, he indirectly owns 22,500 shares through a Family Trust, bringing his total beneficial ownership to 95,206 shares.
